SequelSEC

Vaxcyte, Inc. PCVX

Biological Products, (No Diagnostic Substances) · CIK 0001649094 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2026-06-30
Operating income
-$302.78M
Fiscal year ended 2026-06-30
Free cash flow
-$236.79M
Fiscal year ended 2026-06-30

Vaxcyte, Inc. (PCVX) reported net income of -$284.30M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Vaxcyte, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Vaxcyte, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$302.78MUnavailable-$274.28M-$242.38MUnavailableUnavailable-$162.17M-$139.92MUnavailableUnavailable
Net income-$284.30MUnavailable-$246.51M-$212.83MUnavailableUnavailable-$137.08M-$103.12MUnavailableUnavailable
Research & development$267.85MUnavailable$242.06M$209.93MUnavailableUnavailable$133.61M$116.94MUnavailableUnavailable
Weighted-average diluted sharesshares 144.49MUnavailableUnavailableshares 136.20MUnavailableUnavailableUnavailableshares 123.69MUnavailableUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$0Unavailable$0$0UnavailableUnavailable$0$0UnavailableUnavailable
Diluted EPS$-1.97UnavailableUnavailable$-1.56UnavailableUnavailableUnavailable$-0.83UnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$34.92MUnavailable$32.22M$32.45MUnavailableUnavailable$28.56M$22.99MUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Vaxcyte, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$183.19MUnavailable$173.96M$281.08MUnavailableUnavailable$387.88M$1.05BUnavailableUnavailable
Total assets$3.14BUnavailable$3.00B$3.17BUnavailableUnavailable$3.51B$3.56BUnavailableUnavailable
Current assets$1.55BUnavailable$1.63B$1.77BUnavailableUnavailable$1.79B$2.21BUnavailableUnavailable
Total liabilities$380.21MUnavailable$317.21M$278.72MUnavailableUnavailable$205.50M$142.11MUnavailableUnavailable
Current liabilities$271.28MUnavailable$205.75M$200.05MUnavailableUnavailable$140.18M$123.79MUnavailableUnavailable
Total equity incl. NCI$2.76BUnavailable$2.69B$2.89BUnavailableUnavailable$3.31B$3.42BUnavailableUnavailable
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$100.92MUnavailable$70.90M$48.96MUnavailableUnavailable$48.45M$18.22MUnavailableUnavailable

Cash flow

Vaxcyte, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$232.47MUnavailable-$224.83M-$143.30MUnavailableUnavailable-$111.40M-$60.71MUnavailableUnavailable
Capital expenditures$4.32MUnavailable$2.65M$3.82MUnavailableUnavailable$4.02M$4.95MUnavailableUnavailable
Investing cash flow$147.72MUnavailable$115.12M$121.17MUnavailableUnavailable-$557.17M-$917.02MUnavailableUnavailable
Financing cash flow$5.70MUnavailable$2.41M-$3.67MUnavailableUnavailable$4.91M$1.52BUnavailableUnavailable
Net change in cash-$77.65MUnavailable-$107.12M-$25.52MUnavailableUnavailable-$662.31M$531.73MUnavailableUnavailable
Stock-based compensation$41.24MUnavailable$36.00M$35.31MUnavailableUnavailable$24.37M$21.26MUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$3.00MUnavailable$7.50M$3.06MUnavailableUnavailable$2.86M$1.80MUnavailableUnavailable

Derived

Vaxcyte, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flow-$236.79MUnavailable-$227.49M-$147.13MUnavailableUnavailable-$115.42M-$65.66MUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio5.72xUnavailable7.91x8.83xUnavailableUnavailable12.75x17.88xUnavailableUnavailable
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open PCVX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-05View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-K · Filed 2026-02-24View SEC filing
10-Q · Filed 2025-11-04View SEC filing
10-Q · Filed 2025-08-06View SEC filing
10-Q · Filed 2025-05-07View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Reconciliation checks needing review

14 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2026-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2026-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2025-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2025-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2025-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2025-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2024-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2024-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2023-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2023-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.